YD Bio Limited (YDES) board reshaped by majority holders’ written consent

Rhea-AI Filing Summary

YD Bio Limited reported significant changes to its Board of Directors initiated by its majority shareholders. YD Biopharma Holding Limited and EG Biomed Limited, whose combined holdings represent a majority of the company’s voting rights, delivered a shareholders’ written consent removing four directors and appointing two new ones, effective December 30, 2025. Former directors Joe Douglas Ramsey, Albert Scott McLelland, Michaela Ann Griggs and Janet Hall were removed, while Dr. Kochi Chang and Dr. Shao-Da Lu joined the Board. Both new directors bring long-standing medical and healthcare-related leadership experience, including clinical practice, association leadership and medical device industry roles.

Insights

Corporate governance analyst

Majority shareholders reshaped YD Bio’s board, adding two medically focused directors.

Two shareholders with majority voting power, YD Biopharma Holding Limited and EG Biomed Limited, used a written consent to change the composition of YD Bio’s Board. Four directors were removed and two new directors, Dr. Kochi Chang and Dr. Shao-Da Lu, were elected effective December 30, 2025, in line with the company’s Cayman Islands framework.

Both new directors have extensive backgrounds in medicine and healthcare-related management. Dr. Chang has experience in medical devices, academia and as CEO of Prident International Inc., while Dr. Lu has decades of clinical, clinic management and medical association leadership experience. This shift concentrates board seats with individuals rooted in healthcare, which may influence strategic and operational priorities.

The filing demonstrates that control over board composition rests with the majority shareholders through written consents. Future company disclosures may clarify how the board’s new makeup affects strategy, risk oversight and partnerships.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549 

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the Month of January 2026

Commission File Number: 001-42810

YD Bio Limited

12F., No. 3, Xingnan St.,

Nangang Dist.,

Taipei City 115001, Taiwan

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

Changes in Board of Directors

On January 16, 2026, YD Bio Limited (the “Company” or the “Registrant”) announced that YD Biopharma Holding Limited and EG Biomed Limited, two stockholders of the Company whose combined holdings constitute a majority of the Company’s voting rights, delivered a shareholders’ written consent (the “Written Consent”) to the Company’s registered office pursuant to the Company’s governing documents and the applicable laws of the Cayman Islands. According to the Written Consent, four members of the Company’s Board of Directors (the “Board”), Joe Douglas Ramsey, Albert Scott McLelland, Michaela Ann Griggs and Janet Hall, were removed as directors effective December 30, 2025, and two new directors, Dr. Kochi Chang and Dr. Shao-Da Lu were elected to the Board effective December 30, 2025.

Dr. Kochi Chang has served as a Member of the Advisory Committee at the Intelligent Computing Research Laboratory, California State University of Fullerton, a nonprofit research institution since May 2022. Previously, he was the Director of the Prosthetics Division at Dentsply International, a for-profit manufacturer of medical devices from June 2006 to August 2013. He co-founded and has served as the Chairman and CEO of Prident International Inc. in California since January 2003. Dr. Chang earned his Bachelor of Dentistry degree from the School of Dentistry at Taipei Medical University in Taiwan.

Dr. Shao-Da Lu has served as the Director at Lü Shao-Da Holistic Health Clinic since October 1992. He has served as the Deputy Secretary-General at the National Federation of Medical Doctors’ Associations, Republic of China since Aug 2017. From September 1983 to August 1987, he worked as a specialist in internal medicine at Linkou Chang Gung Memorial Hospital. From September1981 to August 1982, he was a pediatrician at the Taipei Women and Children’s Hospital. He also holds management and directorship positions at several medical professional associations. Dr. Lu earned his M.D. from China Medical University, College of Medicine.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

January 16, 2026

	YD BIO LIMITED
	By:	/s/ Edmund Hen
	Name:	Edmund Hen
	Title:	Chief Financial Officer

2

FAQ

What board changes did YD Bio Limited (YDES) disclose in this 6-K?

YD Bio Limited reported that four directors, Joe Douglas Ramsey, Albert Scott McLelland, Michaela Ann Griggs and Janet Hall, were removed from the Board and two new directors, Dr. Kochi Chang and Dr. Shao-Da Lu, were elected, all effective December 30, 2025.

Who initiated the board changes at YD Bio Limited (YDES)?

The changes were initiated by YD Biopharma Holding Limited and EG Biomed Limited, two shareholders whose combined holdings constitute a majority of YD Bio’s voting rights, through a shareholders’ written consent.

When did the new directors join the YD Bio Limited (YDES) board?

Dr. Kochi Chang and Dr. Shao-Da Lu were elected to the Board effective December 30, 2025, according to the shareholders’ written consent.

What is the background of new YD Bio director Dr. Kochi Chang?

Dr. Kochi Chang serves on the Advisory Committee at the Intelligent Computing Research Laboratory at California State University of Fullerton, previously led the Prosthetics Division at Dentsply International, and has been Chairman and CEO of Prident International Inc. since January 2003. He holds a Bachelor of Dentistry from Taipei Medical University.

What experience does new YD Bio director Dr. Shao-Da Lu bring?

Dr. Shao-Da Lu has directed the Lü Shao-Da Holistic Health Clinic since 1992, serves as Deputy Secretary-General at the National Federation of Medical Doctors’ Associations, Republic of China, and has prior experience as an internal medicine specialist and pediatrician. He earned his M.D. from China Medical University, College of Medicine.

What mechanism was used to change YD Bio Limited’s (YDES) board?

The majority shareholders used a shareholders’ written consent, delivered to the company’s registered office in accordance with its governing documents and Cayman Islands law, to remove four directors and elect two new ones.